vs
Side-by-side financial comparison of Enlight Renewable Energy Ltd. (ENLT) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $109.5M, roughly 1.6× Enlight Renewable Energy Ltd.).
Enlight Renewable Energy is a publicly traded company, headquartered in Israel, that builds and operates solar and wind power facilities. Its shares are traded on the Tel Aviv Stock Exchange and on Nasdaq (ENLT) following the company’s United States initial public offering in February 2023. In addition to solar and wind, Enlight develops utility-scale energy storage and agrivoltaic projects integrating agricultural land use with photovoltaic generation.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
ENLT vs PCRX — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $109.5M | $177.4M |
| Net Profit | — | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 60.1% | 3.9% |
| Net Margin | — | 1.6% |
| Revenue YoY | — | 5.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | $123305879.00 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $109.5M | $196.9M | ||
| Q3 25 | — | $179.5M | ||
| Q2 25 | $84.7M | $181.1M | ||
| Q1 25 | $90.4M | $168.9M | ||
| Q4 24 | $73.8M | $187.3M | ||
| Q3 24 | $58.3M | $168.6M | ||
| Q2 24 | $52.6M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $5.4M | ||
| Q2 25 | — | $-4.8M | ||
| Q1 25 | — | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-143.5M | ||
| Q2 24 | — | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | 48.9% | 76.9% | ||
| Q2 24 | 55.5% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 60.1% | 1.2% | ||
| Q3 25 | — | 3.5% | ||
| Q2 25 | 41.2% | 4.7% | ||
| Q1 25 | 47.4% | 1.2% | ||
| Q4 24 | 58.1% | 13.2% | ||
| Q3 24 | 73.2% | -82.8% | ||
| Q2 24 | 63.7% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 3.0% | ||
| Q2 25 | — | -2.7% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -85.1% | ||
| Q2 24 | — | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $123305879.00 | $0.05 | ||
| Q3 25 | — | $0.12 | ||
| Q2 25 | $125866004.00 | $-0.11 | ||
| Q1 25 | $122889909.00 | $0.10 | ||
| Q4 24 | — | $0.38 | ||
| Q3 24 | $125866004.00 | $-3.11 | ||
| Q2 24 | $125873060.00 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $653.9M |
| Total Assets | — | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | $387.4M | $484.6M | ||
| Q3 24 | — | $453.8M | ||
| Q2 24 | — | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | — | $693.1M | ||
| Q3 25 | — | $727.2M | ||
| Q2 25 | — | $757.8M | ||
| Q1 25 | — | $798.5M | ||
| Q4 24 | $1.4B | $778.3M | ||
| Q3 24 | — | $749.6M | ||
| Q2 24 | — | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | $5.5B | $1.6B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ENLT
| Segment adjusted EBITDA | $99.7M | 91% |
| Tax benefits | $10.1M | 9% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
